|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Cohort name:** | **# of cases with p53 immunostaining:** | **# of cases with *TP53* sequencing:** | **Type of tissue:** | **Type of tissue sampling:** | **Study** | **Reference:** |
| Intermediate/high risk | 322 | 28 | radical prostatectomy | TMA (n=322) and standard slides (n=77) | validation of IHC; outcomes | (32,33) |
| Biochemical recurrence | 195 | 0 | radical prostatectomy | TMA | outcomes | (32,33) |
| Autopsy | 13 | 13 | metastasis (CRPC) | TMA | validation of IHC | (11,34) |
| Small cell carcinoma of prostate | 4 | 4 | biopsy/TURP | TMA | validation of IHC | (6) |
| *TP53* copy number | 2 | 0 | radical prostatectomy | Standard slides | validation of IHC | (35) |
| Abiraterone/enzalutamide | 56 | 56 | radical prostatectomy | TMA | validation of IHC | Maughan et al, under review |

**Supplementary Table S1**: Tissue cohorts included in the study